Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-1.43 |
-1.42 |
0.01 |
0.70% |
2024-03-07 |
2023-12 |
-0.92 |
-0.8 |
0.12 |
13.04% |
2024-03-07 |
2023-12 |
-0.92 |
N/A |
N/A |
N/A |
2023-11-09 |
2023-09 |
-0.95 |
-0.76 |
0.19 |
20.00% |
2023-11-09 |
2023-09 |
-0.95 |
N/A |
N/A |
N/A |
2023-08-10 |
2023-06 |
-0.95 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-26 |
Needham |
Upgrade |
Buy |
Buy |
2023-08-10 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-10 |
Needham |
Upgrade |
Buy |
Buy |
2023-08-08 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-06-11 |
Needham |
Upgrade |
|
Buy |
2023-05-10 |
Evercore ISI Group |
Upgrade |
In-Line |
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2024-05-22 |
COLA MICHAEL F |
Director |
29.30K |
Stock Award(Grant) |
2024-03-21 |
CURRAN TERRIE |
Chief Executive Officer |
414.62K |
Sale |
2024-05-22 |
FIELDS-KUNZ HEIDI |
Director |
19.50K |
Stock Award(Grant) |
2024-04-07 |
HENDERSON MOLLY |
Chief Financial Officer |
97.17K |
Sale |
2024-05-22 |
KARBE FRANK L |
Director |
19.50K |
Stock Award(Grant) |
2024-05-22 |
PARIKH ASIT |
Director |
65.50K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Frazier Life Sciences Management, L.P. |
10.11M |
144.76M |
17.80% |
2023-09-29 |
Medicxi Ventures Management (Jersey) Ltd |
3.76M |
39.00M |
6.62% |
2023-06-29 |
Carlyle Group Inc. |
3.50M |
50.07M |
6.16% |
2023-06-29 |
Invesco Ltd. |
3.33M |
47.72M |
5.87% |
2023-06-29 |
Blackrock Inc. |
2.00M |
28.68M |
3.53% |
2023-06-29 |
Avidity Partners Management, LP |
1.95M |
27.92M |
3.43% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-07-30 |
Invesco Global Fund |
1.76M |
26.78M |
3.10% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.11M |
15.87M |
1.95% |
2023-08-30 |
iShares Russell 2000 ETF |
569.98K |
8.20M |
1.00% |
2023-06-29 |
Invesco V.I. Global Fund |
396.04K |
5.67M |
0.70% |
2023-06-29 |
Vanguard Extended Market Index Fund |
331.35K |
4.74M |
0.58% |
2023-06-29 |
JNL Series Trust-JNL/Invesco Global Growth Fund |
317.29K |
4.54M |
0.56% |